Candel Therapeutics Reports Positive Phase 3 Results for Prostate Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Candel Therapeutics announced significant progress in treating high-risk localized prostate cancer, with a 30% improvement in disease-free survival (DFS) reported in 745 patients, as published in The Lancet Oncology, indicating the therapy's potential to enhance patient outcomes.
- Survival Rate Improvement: The combination of Aglatimagene with standard radiotherapy and Valacyclovir resulted in a 38% increase in prostate cancer-specific DFS compared to placebo, with a follow-up period revealing a 39% rate, demonstrating the drug's long-term efficacy.
- Biomarker Analysis: A post-hoc blinded review conducted two years post-radiotherapy showed that 80% of patients treated with Aglatimagene had negative biopsy results, compared to 63% in the placebo group, further validating the therapy's effectiveness and safety profile.
- Safety Profile: Aglatimagene exhibited a generally favorable safety profile, and its use in conjunction with existing treatment options may provide new therapeutic avenues for high-risk prostate cancer patients, enhancing Candel Therapeutics' competitive position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CADL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CADL
Wall Street analysts forecast CADL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.560
Low
7.00
Averages
18.33
High
25.00
Current: 8.560
Low
7.00
Averages
18.33
High
25.00
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Candel's Phase 3 Prostate Cancer Therapy Data Released
- Promising Phase 3 Data: Candel Therapeutics published Phase 3 data for its prostate cancer therapy Aglatimagene Besadenovec, showing a 30% improvement in disease-free survival when combined with standard radiotherapy, indicating significant efficacy that is expected to support the upcoming Biologics License Application.
- Patient Enrollment Success: The randomized trial enrolled 745 patients and met its primary endpoint with a 38% improvement in prostate cancer-specific disease-free survival, not only validating the therapy's effectiveness but also establishing a strong foundation for the company's position in the competitive biopharmaceutical market.
- Positive Market Reaction: Candel's stock saw a pre-market boost on Friday as investors remained upbeat about the Phase 3 trial results, putting the stock on track for its best week in a month, reflecting market confidence in the company's future growth potential.
- Optimistic Analyst Ratings: According to Koyfin data, Candel's stock has an average 12-month price target of $19.63, representing a potential upside of around 111%, and carries a Strong Buy consensus rating, indicating high recognition of its prospects among analysts.
See More
Candel Therapeutics Reports Positive Phase 3 Results for Prostate Cancer Treatment
- Clinical Trial Results: Candel Therapeutics announced significant progress in treating high-risk localized prostate cancer, with a 30% improvement in disease-free survival (DFS) reported in 745 patients, as published in The Lancet Oncology, indicating the therapy's potential to enhance patient outcomes.
- Survival Rate Improvement: The combination of Aglatimagene with standard radiotherapy and Valacyclovir resulted in a 38% increase in prostate cancer-specific DFS compared to placebo, with a follow-up period revealing a 39% rate, demonstrating the drug's long-term efficacy.
- Biomarker Analysis: A post-hoc blinded review conducted two years post-radiotherapy showed that 80% of patients treated with Aglatimagene had negative biopsy results, compared to 63% in the placebo group, further validating the therapy's effectiveness and safety profile.
- Safety Profile: Aglatimagene exhibited a generally favorable safety profile, and its use in conjunction with existing treatment options may provide new therapeutic avenues for high-risk prostate cancer patients, enhancing Candel Therapeutics' competitive position in the biopharmaceutical sector.
See More
Candel Plans to Submit New Drug Application
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
See More
Candel Plans to Submit Biologics License Application
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
See More
Candel Therapeutics Reports Earnings, Stock Volatility Observed
- Earnings Beat Expectations: Candel Therapeutics reported a loss of $0.14 per share, significantly better than the consensus estimate of a $0.33 loss, indicating improved financial management that could bolster investor confidence.
- Upcoming Data Presentation: The company is set to present pivotal follow-up data from its Phase 3 prostate cancer trial at the 2026 American Urological Association annual meeting, and positive results could drive stock price increases and attract more investor interest.
- New Lung Cancer Trial: Candel plans to initiate a Phase 3 trial for lung cancer treatment in June 2026, leveraging promising data from a Phase 2 trial where half of the 46 patients survived over 24 months, showcasing the treatment's potential.
- Bullish Market Sentiment: Investor sentiment on Stocktwits is trending bullish with high message volumes, as some users predict that positive follow-up data could push the stock past $12, currently trading around $9, reflecting market optimism about the company's future.
See More
Candel Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Surprise: Candel Therapeutics reported a Q1 GAAP EPS of -$0.14, beating market expectations by $0.19, indicating improvements in financial management and increased market confidence.
- Strong Cash Position: As of March 31, 2026, the company holds $194.8 million in cash and cash equivalents, expected to fund its operating plan into Q1 2028, ensuring financial stability for the next two years.
- Commercialization Plans: Candel is preparing for the potential commercial launch of its cancer vaccine aglatimagene in 2027, with current funding supporting these activities, reflecting the company's confidence in future market opportunities.
- Public Offering Activity: Candel Therapeutics has launched a $100 million public stock offering; although shares have declined, this move will further strengthen the company's capital base to support its R&D and marketing efforts.
See More
Candel's Phase 3 Prostate Cancer Therapy Data Released
- Promising Phase 3 Data: Candel Therapeutics published Phase 3 data for its prostate cancer therapy Aglatimagene Besadenovec, showing a 30% improvement in disease-free survival when combined with standard radiotherapy, indicating significant efficacy that is expected to support the upcoming Biologics License Application.
- Patient Enrollment Success: The randomized trial enrolled 745 patients and met its primary endpoint with a 38% improvement in prostate cancer-specific disease-free survival, not only validating the therapy's effectiveness but also establishing a strong foundation for the company's position in the competitive biopharmaceutical market.
- Positive Market Reaction: Candel's stock saw a pre-market boost on Friday as investors remained upbeat about the Phase 3 trial results, putting the stock on track for its best week in a month, reflecting market confidence in the company's future growth potential.
- Optimistic Analyst Ratings: According to Koyfin data, Candel's stock has an average 12-month price target of $19.63, representing a potential upside of around 111%, and carries a Strong Buy consensus rating, indicating high recognition of its prospects among analysts.
See More
Candel Therapeutics Reports Positive Phase 3 Results for Prostate Cancer Treatment
- Clinical Trial Results: Candel Therapeutics announced significant progress in treating high-risk localized prostate cancer, with a 30% improvement in disease-free survival (DFS) reported in 745 patients, as published in The Lancet Oncology, indicating the therapy's potential to enhance patient outcomes.
- Survival Rate Improvement: The combination of Aglatimagene with standard radiotherapy and Valacyclovir resulted in a 38% increase in prostate cancer-specific DFS compared to placebo, with a follow-up period revealing a 39% rate, demonstrating the drug's long-term efficacy.
- Biomarker Analysis: A post-hoc blinded review conducted two years post-radiotherapy showed that 80% of patients treated with Aglatimagene had negative biopsy results, compared to 63% in the placebo group, further validating the therapy's effectiveness and safety profile.
- Safety Profile: Aglatimagene exhibited a generally favorable safety profile, and its use in conjunction with existing treatment options may provide new therapeutic avenues for high-risk prostate cancer patients, enhancing Candel Therapeutics' competitive position in the biopharmaceutical sector.
See More
Candel Plans to Submit New Drug Application
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
See More
Candel Plans to Submit Biologics License Application
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
See More
Candel Therapeutics Reports Earnings, Stock Volatility Observed
- Earnings Beat Expectations: Candel Therapeutics reported a loss of $0.14 per share, significantly better than the consensus estimate of a $0.33 loss, indicating improved financial management that could bolster investor confidence.
- Upcoming Data Presentation: The company is set to present pivotal follow-up data from its Phase 3 prostate cancer trial at the 2026 American Urological Association annual meeting, and positive results could drive stock price increases and attract more investor interest.
- New Lung Cancer Trial: Candel plans to initiate a Phase 3 trial for lung cancer treatment in June 2026, leveraging promising data from a Phase 2 trial where half of the 46 patients survived over 24 months, showcasing the treatment's potential.
- Bullish Market Sentiment: Investor sentiment on Stocktwits is trending bullish with high message volumes, as some users predict that positive follow-up data could push the stock past $12, currently trading around $9, reflecting market optimism about the company's future.
See More
Candel Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Surprise: Candel Therapeutics reported a Q1 GAAP EPS of -$0.14, beating market expectations by $0.19, indicating improvements in financial management and increased market confidence.
- Strong Cash Position: As of March 31, 2026, the company holds $194.8 million in cash and cash equivalents, expected to fund its operating plan into Q1 2028, ensuring financial stability for the next two years.
- Commercialization Plans: Candel is preparing for the potential commercial launch of its cancer vaccine aglatimagene in 2027, with current funding supporting these activities, reflecting the company's confidence in future market opportunities.
- Public Offering Activity: Candel Therapeutics has launched a $100 million public stock offering; although shares have declined, this move will further strengthen the company's capital base to support its R&D and marketing efforts.
See More
